HUBEI JUMPCAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.96 CNY | +0.05% |
|
+5.52% | +39.87% |
| Sales 2024 * | 9.9B 1.37B | Sales 2025 * | 11.71B 1.62B | Capitalization | 40.52B 5.6B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.02B 416M | Net income 2025 * | 3.25B 449M | EV / Sales 2024 * | 4.09 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.46 x |
| P/E ratio 2024 * |
13.4
x | P/E ratio 2025 * |
12.5
x | Employees | 5,230 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 35.84% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.05% | ||
| 1 week | +5.52% | ||
| Current month | +17.45% | ||
| 1 month | +19.17% | ||
| 3 months | +37.33% | ||
| 6 months | +69.34% | ||
| Current year | +39.87% |
1 week
41.66
45.18
1 month
35.1345.18
Current year
28.6045.18
1 year
23.9545.18
3 years
14.3745.18
5 years
14.3745.18
10 years
14.3754.97
| Managers | Title | Age | Since |
|---|---|---|---|
Fei Cao
CEO | Chief Executive Officer | 41 | 14-03-09 |
Hong Cun Yan
DFI | Director of Finance/CFO | 56 | 14-03-09 |
Long Xiang Cao
CHM | Chairman | 67 | 14-03-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Long Xiang Cao
CHM | Chairman | 67 | 14-03-09 |
Qu Rong Huang
BRD | Director/Board Member | 62 | 14-03-09 |
Fei Cao
CEO | Chief Executive Officer | 41 | 14-03-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.42% | 2 M€ | -19.84% | - | |
| 0.31% | 4 M€ | -2.96% | ||
| 0.19% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 43.96 | +0.05% | 9,603,627 |
| 24-04-17 | 43.94 | +1.06% | 8,414,597 |
| 24-04-16 | 43.48 | +1.52% | 10,457,500 |
| 24-04-15 | 42.83 | +2.34% | 9,211,981 |
| 24-04-12 | 41.85 | +0.46% | 9,275,013 |
End-of-day quote Shanghai S.E., April 17, 2024
More quotes
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD., formerly Hubei Hongcheng General Machinery Co., Ltd., is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products include heat-clearing and detoxifying series, digestive system series, pediatric series, breathing series, cardiovascular series and gynecology series. Its pharmaceuticals consist of tablets, mixtures, injections, capsules, granules and sprays, among others. The Company mainly distributes its products within domestic markets.
Sector
Pharmaceuticals
Calendar
2024-04-19
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
43.96
CNY
Average target price
52.36
CNY
Spread / Average Target
+19.11%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +39.87% | 5.6B | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 600566 Stock
